Thus, our study indicates that although BRAF mutations are rare in myeloid neoplasms, constituting only 0.53% of cases in our cohort, they play a crucial role in the pathogenesis of specific AML subtypes. This evidence concerns the gene BRAF and acute myeloid leukemia.